File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Bone mineral density in premenopausal women receiving long-term physiological doses of levothyroxine

TitleBone mineral density in premenopausal women receiving long-term physiological doses of levothyroxine
Authors
Issue Date1991
PublisherAmerican Medical Association. The Journal's web site is located at http://jama.ama-assn.org/index.dtl
Citation
Journal Of The American Medical Association, 1991, v. 265 n. 20, p. 2688-2691 How to Cite?
AbstractTotal body and regional bone mineral density (BMD) levels were determined in 26 premenopausal women with Hashimoto's thyroiditis receiving long-term physiological doses of levothyroxine sodium replacement therapy. The BMD levels of each patient were compared with the mean of the BMD levels of age-matched normal controls. The mean levothyroxine sodium dose was 111 ± 6 μg/d, and the mean duration of treatment was 7.5 ± 5.3 years (range, 1 to 24 years). Dietary calcium intake was similar in both groups, as were serum thyroxine, triiodothyronine, free thyroxine index, and thyrotropin levels. Women receiving the levothyroxine treatment had normal total body BMD levels but had significantly lower BMD levels at the femoral neck (-5.7%), femoral trochanter (-7.0%), Ward's triangle (-10.6%), both arms (right, -7.8%; left, -8.9%), and pelvis (-4.9%). In contrast, lumbar spine BMD levels were similar in the two groups. There was no correlation between the total body or different regional BMD levels and the duration or dosage of levothyroxine treatment or thyroid function test results. However, the z score of the femoral neck of these patients showed a significant negative correlation with their serum free thyroxine index levels. We conclude that patients receiving physiological doses of levothyroxine may have decreased bone density. Thyroid functions in patients receiving long-term levothyroxine treatment should be closely monitored and bone densitometry should be performed in patients at risk for osteoporosis.
Persistent Identifierhttp://hdl.handle.net/10722/161858
ISSN
2015 Impact Factor: 37.684
2015 SCImago Journal Rankings: 6.440
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKung, AWCen_US
dc.contributor.authorPun, KKen_US
dc.date.accessioned2012-09-05T05:15:33Z-
dc.date.available2012-09-05T05:15:33Z-
dc.date.issued1991en_US
dc.identifier.citationJournal Of The American Medical Association, 1991, v. 265 n. 20, p. 2688-2691en_US
dc.identifier.issn0098-7484en_US
dc.identifier.urihttp://hdl.handle.net/10722/161858-
dc.description.abstractTotal body and regional bone mineral density (BMD) levels were determined in 26 premenopausal women with Hashimoto's thyroiditis receiving long-term physiological doses of levothyroxine sodium replacement therapy. The BMD levels of each patient were compared with the mean of the BMD levels of age-matched normal controls. The mean levothyroxine sodium dose was 111 ± 6 μg/d, and the mean duration of treatment was 7.5 ± 5.3 years (range, 1 to 24 years). Dietary calcium intake was similar in both groups, as were serum thyroxine, triiodothyronine, free thyroxine index, and thyrotropin levels. Women receiving the levothyroxine treatment had normal total body BMD levels but had significantly lower BMD levels at the femoral neck (-5.7%), femoral trochanter (-7.0%), Ward's triangle (-10.6%), both arms (right, -7.8%; left, -8.9%), and pelvis (-4.9%). In contrast, lumbar spine BMD levels were similar in the two groups. There was no correlation between the total body or different regional BMD levels and the duration or dosage of levothyroxine treatment or thyroid function test results. However, the z score of the femoral neck of these patients showed a significant negative correlation with their serum free thyroxine index levels. We conclude that patients receiving physiological doses of levothyroxine may have decreased bone density. Thyroid functions in patients receiving long-term levothyroxine treatment should be closely monitored and bone densitometry should be performed in patients at risk for osteoporosis.en_US
dc.languageengen_US
dc.publisherAmerican Medical Association. The Journal's web site is located at http://jama.ama-assn.org/index.dtlen_US
dc.relation.ispartofJournal of the American Medical Associationen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshBone Density - Physiologyen_US
dc.subject.meshCalcium, Dietaryen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMenopauseen_US
dc.subject.meshThyroid Function Testsen_US
dc.subject.meshThyroiditis, Autoimmune - Drug Therapy - Physiopathologyen_US
dc.subject.meshThyroxine - Therapeutic Useen_US
dc.titleBone mineral density in premenopausal women receiving long-term physiological doses of levothyroxineen_US
dc.typeArticleen_US
dc.identifier.emailKung, AWC:awckung@hku.hken_US
dc.identifier.authorityKung, AWC=rp00368en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1001/jama.265.20.2688en_US
dc.identifier.pmid2023349-
dc.identifier.scopuseid_2-s2.0-0025733542en_US
dc.identifier.volume265en_US
dc.identifier.issue20en_US
dc.identifier.spage2688en_US
dc.identifier.epage2691en_US
dc.identifier.isiWOS:A1991FL98900033-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridKung, AWC=7102322339en_US
dc.identifier.scopusauthoridPun, KK=7006538877en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats